Commercial leaders can boost product launches with a data-driven roadmap.
Daniel Patrick discusses the small biotech company journey from an incubator of ideas to the ability to shepherd an R&D asset through its pipeline to achieving commercial success.
Designing and managing clinical outcome assessments on an international basis is more than a translation task. It requires the more discrete practice of linguistic validation, writes Dana Weiss.
To be successful, healthcare organizations must delve into optimizing leadership skills and building a deep pipeline of executive-ready talent.
One of the most important jobs of a biotech executive is building a strong team that will not only keep a company competitive in the current market, but will also have the stamina to carry it into the future.
A list of three key elements when looking at public-private partnerships to tackle public health challenges.
Chad Storlie draws on military training to outline how all industries and organisations can create great junior leaders.
Maude Schmidt and Giovanni Saldutti look at the intergovernmental initiatives involving joint price negotiations developed across Europe as the Beneluxa Initiative on Pharmaceutical Policy to explore the outcomes and implications from these alliances.
Benefit verification (BV) provides a detailed understanding of out of pocket costs for the prescribed treatment. Amy Jones details how AI is aiding the BV process.
Analytics as a service can provide critical accelerators for the commercial transformation program at a life sciences organization, writes Himanshu Jain.
Many real-world data sources contain unstructured text, making it difficult and time-consuming to glean actionable insights from the data. Natural language processing technology can alleviate this problem, writes Jane Z. Reed.
To succeed in developing targeted medicines, companies need a biomarker strategy and the expertise to make smart decisions about clinical trial design, assays, technology platforms and collaborative partners, write Barry S. Sall and Angela X. Qu.
An overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
An overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
Upcoming regulatory changes to create new opportunity for specialized offerings.
An overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
An overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
A list of five essential features a building must have in order to be considered lab-ready.
How low-cost drugs can succeed in the specialty pharmacy channel.
The marketing challenge for pharmaceutical companies has now shifted to "How can we successfully and cost-effectively assist providers in orchestrating better care?" William Febbo reports.
For pharma leaders, AI can bring about a new reality of seeing a multitude of possible paths, forecasting the interplay of multi-dimensional trends, and charting patient journeys that are based on reality, writes Aswin Chandrakantan.
Small biotech companies benefit more from partnering with CROs rather than hiring a chief medical officer.
Thee most effective way to train sales reps and boost their success is to consider the learner/user experience in all facets, in every training encounter, and on each training platform, writes Shaun McMahon.
With employers and the public scrutinizing drug prices like never before, rebates-long at the center of pharma’s market access strategy-may be losing their luster, writes Amber Gilbert.
A look at the Drug SUpply Chain Security Act and how it impacts serialization and third-party logistics licensing.
Overcoming the challenges of digital brand management will involve choices in spending and channels.
The call to reduce market entry times for life-saving new drug therapies is becoming more urgent. What constitutes best practice in managing translations in today’s regulatory affairs environment? Nancy Pollini reports.